文献速递自身炎症与 IgG4 相关病

VEXAS综合征疾病活动指数(VEXAS-DAI)的制定

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-07-13

本研究旨在为VEXAS综合征开发一个全面的疾病活动指数(DAI),以评估受累器官系统的炎症活动。通过改良德尔菲法,跨国专家咨询委员会经四轮达成共识,制定了涵盖12个领域的VEXAS-DAI,总分范围为0至40分。该指数是量化VEXAS患者活动性炎症的新工具,目前正在临床试验环境中进行前瞻性验证。

要点

  • VEXAS-DAI涵盖12个炎症领域,总分0-40分,用于评估VEXAS疾病活动度。
  • 该指数通过改良德尔菲法经四轮达成共识制定,共识阈值定义为≥75%一致。
  • VEXAS-DAI尚需前瞻性临床试验验证,目前正在进行中。

核心结论

  • VEXAS-DAI是一种新型工具,旨在量化VEXAS综合征患者随时间变化的活动性炎症。

研究设计与样本

  • 通过系统文献回顾和专家输入识别VEXAS的炎症表现,跨国专家咨询委员会采用改良德尔菲法制定VEXAS-DAI,直至达到共识(定义为≥75%一致)。
  • 项目分级改编自常见不良事件评价标准(CTCAE),评分标准基于158个测试案例并使用医生整体炎症评估(Physician Global Assessment of Inflammation)开发。

主要发现

  • 经过四轮德尔菲回合,就VEXAS-DAI达成共识。
  • 该指数评估评估时的炎症活动,涵盖12个领域:炎症性皮疹、软骨炎、眶周、眼科、关节、肺部、心血管、泌尿生殖、神经、口腔和胃肠道、肾脏以及全身症状。
  • 总分范围为0至40分。

关键数值与推荐

  • 共识定义为≥75%一致。
  • VEXAS-DAI总分范围为0至40分。
  • 评分标准基于158个测试案例开发。

临床怎么用

  • VEXAS-DAI可用于量化VEXAS综合征患者的活动性炎症,支持临床研究和患者管理。
  • 该指数目前正在临床试验环境中进行前瞻性验证,尚未常规用于临床实践。

局限性

  • VEXAS-DAI尚未经过前瞻性验证,验证研究正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS-specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease activity over time, thereby supporting clinical research and informing patient care in this emerging disease. This study aimed to develop a comprehensive DAI to assess disease-related inflammation across affected organ systems in patients with VEXAS syndrome. METHODS: Inflammatory manifestations of VEXAS were previously identified through a systematic literature review and expert input. A multinational expert advisory committee developed the VEXAS-DAI using modified Delphi methodology until consensus (defined as ≥75% concurrence) was reached. Item grading was adapted from the Common Terminology Criteria for Adverse Events. Scoring criteria were developed based on 158 test cases using the Physician Global Assessment of Inflammation. RESULTS: Consensus on the VEXAS-DAI was achieved after four Delphi rounds. The index assesses inflammatory activity at the time of evaluation across 12 domains: inflammatory rash, chondritis, periorbital, ophthalmologic, joint, pulmonary, cardiovascular, genitourinary, neurologic, oral and gastrointestinal, renal, and constitutional symptoms. The total score ranges from 0 to 40. CONCLUSION: The VEXAS-DAI is a novel instrument designed to quantify active inflammation over time in patients with VEXAS. Prospective validation within a clinical trial setting is ongoing.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Byram K, Mann H, Hammond D, et al. Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI). Arthritis Care Res (Hoboken). 2026. PMID: 42439317. doi:10.1002/acr.80117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。